Timing of Maternal COVID-19 Vaccine and Antibody Concentrations in Infants Born Preterm
JAMA Network Open · 2024
DOI: 10.1001/jamanetworkopen.2023.52387 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Alisa Kachikis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University of Washington, Seattle. Hauptthemen laut MEDLINE: Premature Birth, COVID-19, Cone-Rod Dystrophies. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NIAID NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Importance COVID-19 vaccine–derived antibodies in pregnant people may protect infants from severe infection in the first 6 months of life via transplacental antibody transfer. Few data exist on maternally derived SARS-CoV-2 antibodies in preterm compared with full-term infants in association with vaccination timing.
Objective
To compare SARS-CoV-2 anti-Spike (anti-S) antibody levels in preterm and full-term infants in the context of vaccine dose timing before delivery. Design, Setting, and Participants This prospective cohort study enrolled pregnant individuals and collected paired maternal and cord blood samples at delivery at the University of Washington between February 1, 2021, and January 31, 2023. Participants who had received at least 2 doses of a messenger RNA COVID-19 vaccine before delivery and did not have a history of prior COVID-19 infection or detectable anti–SARS-CoV-2 nucleocapsid antibodies were included. Exposures Timing of the last vaccine dose and preterm or full-term gestational age at delivery. Main Outcomes and Measures Paired maternal and cord samples were tested for anti-S antibody, and linear regression was used to evaluate associations between preterm delivery and anti-S antibody levels. Covariates included timing of last dose, number of doses, insurance status, and immunosuppressing medications.
Results
A total of 220 participants (median [IQR] age, 34 [32-37] years; 212 [96.4%] female) with 36 preterm and 184 full-term deliveries were studied. Before delivery, 121 persons received 2 vaccine doses and 99 persons received 3 or more vaccine doses. The geometric mean concentration of maternal anti-S antibodies was 674 (95% CI, 577-787) after 2 doses and 8159 (95% CI, 6636-10 032) after 3 or more doses ( P < .001). The cord anti-S antibody geometric mean concentration was 1000 (95% CI, 874-1144) after 2 doses and 9992 (95% CI, 8381-11 914) after 3 or more doses ( P < .001). After adjustment for vaccine timing and number of doses before delivery, no association was found between preterm delivery and cord anti-S antibody levels (β = 0.44; 95% CI, −0.06 to 0.94). Conclusions and Relevance In this prospective cohort study of pregnant individuals with preterm and full-term deliveries, receipt of 3 or more compared with 2 doses of COVID-19 vaccine before delivery resulted in 10-fold higher cord anti-S antibody levels. Maternal antibody concentration appeared more important than delivery gestational age in determining cord anti-S antibody levels. The number of doses and timing considerations for COVID-19 vaccine in pregnancy should include individuals at risk for preterm delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, University of Washington, Seattle.
- Department of Global Health, University of Washington, Seattle.
- Department of Obstetrics and Gynecology, University of California, San Diego.
- School of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Department of Laboratory Medicine, University of Washington, Seattle.
- Seattle Children's Hospital Research Institute, Department of Pediatrics, University of Washington, Seattle.
Förderung
- NICHD NIH HHS
- NIAID NIH HHS
- NCATS NIH HHS
Zitieren
APA
Kachikis, A., Pike, M., Eckert, L. O., Roberts, E., Frank, Y., Young, A. L., Goecker, E., Gravett, M. G., Greninger, A. L., & Englund, J. A. (2024). Timing of Maternal COVID-19 Vaccine and Antibody Concentrations in Infants Born Preterm. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.52387
Vancouver
Kachikis A, Pike M, Eckert LO, Roberts E, Frank Y, Young AL, et al. Timing of Maternal COVID-19 Vaccine and Antibody Concentrations in Infants Born Preterm. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2023.52387
BibTeX
@article{Kachikis2024,
author = {Kachikis, Alisa and Pike, Mindy and Eckert, Linda O and Roberts, Emma and Frank, Yael and Young, Amber L and Goecker, Erin and Gravett, Michael G and Greninger, Alexander L and Englund, Janet A},
title = {Timing of Maternal COVID-19 Vaccine and Antibody Concentrations in Infants Born Preterm},
journal = {JAMA Network Open},
year = {2024},
doi = {10.1001/jamanetworkopen.2023.52387}
}
EUVIMED